Paris-based Aqemia, which aims to scale drug discovery using quantum algorithms and AI, raised $38M led by Cathay Innovation, after raising €30M in January 2024
Aqemia, a French startup that's meshing “quantum-inspired physics” with machine learning to find new drugs …
Context & Ripple Effects
Aqemia’s $38M round extends its earlier €30M financing for quantum-physics and AI drug discovery, shifting the story from initial backing toward funding the company’s stated effort to scale its platform. Cathay Innovation’s lead also ties the company to a Paris funding ecosystem that has backed another biology-model developer, Bioptimus.
First-order effects
- Aqemia gains $38M to expand the development and scaling of its quantum-algorithm and AI approach to drug discovery.
- Cathay Innovation becomes the lead investor in Aqemia’s next financing step, increasing its exposure to AI-led biology platforms in Paris.
Second-order effects
- The follow-on round raises the competitive bar for other drug-discovery software companies: investors can now compare their ability to turn technical claims into a scalable operating platform against Aqemia’s newly financed plan.
- Cathay’s backing of both Aqemia and Bioptimus’s biology foundation-model effort strengthens the case for investors to treat AI-for-biology as a set of distinct platform bets rather than a single model category.
Third-order effects
- If repeat financings continue, AI-enabled drug discovery may develop around specialized technical stacks—physics-informed methods, biological foundation models, and related tools—rather than one general-purpose approach.
- The pattern could make Paris more consequential as a hub for AI-biology company formation, though the coverage does not establish whether funding will translate into durable commercial or scientific differentiation.
The trend: Specialist investors are increasingly funding differentiated AI-for-biology platforms, including quantum-inspired approaches, as companies move from technical promise toward scale.